Biomarkers Market worth $112.10 billion by 2031
The report "Biomarkers Market by Offering (Consumables, Software, Service), Type (Safety, Efficacy, Validation), Research Area (Genomics, Proteomics), Technology (PCR, NGS, MS), Disease (Cancer, CVD), Application (Diagnostic, Drug Discovery) - Global Forecast to 2031", The global biomarkers market is projected to reach USD 112.10 billion by 2031 from USD 67.95 billion in 2026, at a CAGR of 10.5% during the forecast period. The global biomarkers market is growing due to technological advancements in omics and high-throughput platforms, as well as the increasing adoption of precision medicine and personalized therapeutics.
Browse 690 market data Tables and 65 Figures spread through 515 Pages and in-depth TOC on "Biomarkers Market by Offering (Consumables, Software, Service), Type (Safety, Efficacy, Validation), Research Area (Genomics, Proteomics), Technology (PCR, NGS, MS), Disease (Cancer, CVD), Application (Diagnostic, Drug Discovery) - Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/biomarkers-advanced-technologies-and-global-market-43.html
By research area, the genomics segment accounted for the largest share of the global biomarkers market in 2025.
The global biomarkers market is segmented into genomics, proteomics, metabolomics, and other research areas. Genomics is the largest segment of the biomarkers market because it enables comprehensive analysis of DNA, RNA, and genomic variants associated with diseases, facilitating the identification of specific biomarkers. The high-throughput capabilities of genomics, including next-generation sequencing and microarray analysis, enable the rapid discovery and validation of biomarkers that are predictive, prognostic, and diagnostic. Furthermore, genomics supports the practice of personalized medicine by linking genetic information to drug responses, thereby helping stratify patients for clinical trials. Increased investment in genomics research, the expansion of data assets, and decreasing sequencing costs have all contributed to the growing adoption of genomics. As a result, genomics provides valuable and scalable insights across oncology, rare diseases, and immunology, solidifying its position as the leading area of research in the field of biomarkers.
In 2025, the NGS segment is expected to be the fastest-growing in the global biomarkers market, by technology.
The global biomarkers market is divided by technology into several categories: immunoassays, next-generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, chromatography, and other technologies. Among these, NGS technology is projected to experience the highest compound annual growth rate (CAGR) during the forecast period of 2026 to 2031. This high-throughput DNA and RNA sequencing method can process millions of fragments simultaneously, enabling faster, more comprehensive genomic profiling. It supports key biomarker applications, including whole-genome/exome sequencing, gene panels, RNA sequencing, and single-cell analysis, which facilitate the discovery and validation of complex genomic, transcriptomic, and epigenetic markers in oncology and other fields.
North America accounted for the largest share of the global biomarkers market in 2025.
The global biomarkers market is divided into several regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America holds the largest share of regional revenues. This dominance is largely due to the presence of numerous biopharmaceutical companies, top-tier academic medical centers, and advanced reference laboratories in the US. Additionally, stringent FDA regulations and a rapid adoption of innovative diagnostics and companion tests contribute to this leadership. The extensive pipelines in oncology and immunology, significant funding from the National Institutes of Health (NIH) and cancer research initiatives, and a robust network for clinical trials further establish the US as a powerhouse for biomarker demand in North America.
Key players in the biomarkers market include F. Hoffmann-La Roche Ltd. (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc (US), Abbott (US), QIAGEN (Netherlands), Agilent Technologies, Inc. (US), Revvity (US), and Charles River Laboratories (US).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Biomarkers Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
